Background {#Sec1}
==========

Pharyngeal carcinoma incidence worldwide is approximately 136,000 \[[@CR1]\]. Between 1983 and 2002, an examination of 23 countries across four continents noted a significant rise in oropharyngeal squamous cell carcinoma (OPSCCA), particularly in young men in economically developed countries \[[@CR2]\]. There are now approximately 13,000 new cases diagnosed annually. Historically, as with other mucosal head and neck subsites, etiology of OPSCCA was thought to be primarily secondary to tobacco and alcohol use. We now know human papilloma virus (HPV) to be a major driver of OPSCCA. While the overall incidence of HPV-negative OPSCCA decreased alongside declining smoking rates between 1988 and 2004, HPV-associated OPSCCA has increased by nearly 7.5 % per year, from approximately 16 % of all OPSCCA in the early 1980′s to nearly 70 % today, and is believed will continue to increase dramatically in the coming years \[[@CR3]--[@CR8]\].

The presence of HPV has served as a significant prognosticator in terms of survival in OPSCCA, first reported in the late 1990′s \[[@CR4], [@CR6], [@CR9]\]. Excellent treatment response rates (\>80 %) correspond with the improved survival, and are preserved regardless of specific treatment modality \[[@CR10]\]. Differences in three-year progression free survival (which includes subset analysis of RTOG 0129) between HPV-associated and HPV-negative OPSCCA are impressive at 75--82 % and 45--57 %, respectively, with HPV-associated outcomes improving over time, and HPV-negative outcomes remaining stable, and poor \[[@CR3]--[@CR5], [@CR8], [@CR11]--[@CR14]\]. Locoregional failure at three years is also significantly lower in the HPV-associated patient compared to HPV-negative, at 13.6 % VS 35 %, respectively; these differences in survival and failure have been confirmed independently and prospectively \[[@CR4]\]. HPV associated in the context of OPSCCA affords a 51 % lower risk of disease progression, and 58 % lower risk of death. Interestingly, the negative impact of tobacco use on prognosis remains in these patients and is independent of HPV status \[[@CR3]\]. Regarding recurrences, the majority occur within the first year after treatment and are locoregional \[[@CR15]\]. While the rate of locoregional failure in HPV-associated OPSCCA is lower, the rates of distant metastasis are similar to HPV-negative OPSCCA, with the lung being the most common site of failure \[[@CR15]\]. Fortunately, even in the context of recurrent and/or metastatic disease, HPV association serves as a favorable prognosticator, and consequently aggressive treatment in both these settings may remain justified.

In addition to survival and failure differences, marked differences in clinical presentation characteristics have been noted. Historically, the "typical" head and neck cancer (HNC) patient is of advanced age and with significant substance abuse history. Today, the HPV-associated OPSCCA patient is noted to be younger (between 4th and 6th decade), male (8:1, M:F), with no/minor smoking history, predominantly Caucasian, increased education, married, and higher income \[[@CR8]\]. In terms of exam characteristics, HPV-associated lesions commonly present with comparatively smaller primary tumor (less than 4 cm), and comparatively more advanced nodal disease, which leads to a high TNM and overall stage which may overestimate disease severity as it relates to other head and neck cancers \[[@CR16], [@CR17]\].

Given the marked difference in clinical presentation and treatment response based on HPV status, HPV-associated OPSCCA is now viewed as a distinct biologic and clinical entity. Consequently, novel staging systems have been proposed and validated for the staging of HPV-associated OPSCCA to better represent disease severity/prognosis, though none formally adopted at this time \[[@CR18]\]. In addition, current treatment guidelines do not account for or recommend modifications based on HPV status, but likely will in the future. Several clinical trials are enrolling HPV-associated OPSCCA patients, assessing surgical intervention, radiation de-escalation, and alterations in systemic therapy. These carefully planned de-intensification strategies focus on treatment modifications which will preserve disease control and minimize both long and short term morbidity in selected groups of OPSCCA patients based on T stage, N stage, and smoking status \[[@CR19]--[@CR21]\].

This review aims to provide considerations between management strategies for HPV-associated OPSCCA, noting that at the current time, curative treatment for many of these patients outside the context of clinical trial may include multiple modalities. While no level 1 data exists which provides a comparison between surgical and non-surgical approaches in HPV-associated OPSCCA, and previous retrospective studies are with expected limitations and selection bias, we will discuss clinical considerations and decision-making associated with both of these approaches.

Treatment modalities {#Sec2}
====================

Treatment options for HPV-associated OPSCCA may be largely divided into radiotherapy, systemic therapy/chemotherapy, and surgical resection. Depending on stage and extent/presence of adverse features, definitive treatment may include a combination of modalities.

Radiation therapy {#Sec3}
-----------------

Intensity modulated radiation therapy (IMRT) has been instrumental in preserving excellent control rates, while improving on treatment-related toxicity, with particular regards to salivary and pharyngeal structures \[[@CR22], [@CR23]\]. For stage 1/2 OPSCCA, IMRT notes impressive two year disease free survival between 82 and 90 %, with two year disease specific survival up to 97 %. Regarding toxicity, rates of xerostomia -- 18 % (grade 2); dysphagia -- 15 % (grade 2); subclinical aspiration -- up to 50 % (though reported incidence of aspiration pneumonia much less at approximately 14 %); hypothyroidism is noted in 28--38 % of patients at three years, though may be as high as 55 % depending on the gland volume and amount of gland receiving over 45 Gy; esophageal stenosis -approximately 5 %; osteoradionecrosis of the mandible - approximately 2.5 %; and need for gastrostomy tube to be placed at some point during or up to one year after treatment is around 4 %, though with prolonged followup, may increase to 16 % \[[@CR23]--[@CR25]\].

Current dosing strategies are largely based on randomized trials which lack predominant HPV-associated OPSCCA cohorts. As a result, the optimal treatment and dosing strategy is still in the process of being determined. Unilateral neck radiation for lateralized tonsil cancer is warranted, while bilateral neck radiation is commonplace for tongue base primaries. The potential for unilateral neck radiation in the context of lateralized tongue base cancer is one for debate at this time. Regarding delivery, neither RTOG 9003 nor RTOG 0129 revealed altered fractionation to deliver a survival advantage over standard once-daily fractionation \[[@CR26], [@CR27]\].

Currently, guideline dosing recommendations have not been altered based on HPV status, nor recommended outside the context of a clinical trial. Retrospective analysis of node positive HPV-associated OPSCCA noted a 96 % five year regional control after dose de-escalated radiotherapy (54 Gy), with 90 % receiving concurrent cisplatin based chemotherapy \[[@CR28]\]. A prospective trial (ECOG 1308) also de-intensified to 54Gy with excellent locoregional control \[[@CR29]\]. Radiation dose de-escalation is a major area of interest since short and particularly long term toxicities are largely attributable to radiation dose. Many patients with HPV-associated OPSCCA will survive 30-plus years post-treatment and thus have increased opportunity to fall victim to long-term side effects.

While radiation is commonly utilized concurrently with chemotherapy, radiation monotherapy is a potential effective modality as well and is typically reserved for early stage HPV-associated OPSCCA (T1-T2, N0-1). Indications for radiation monotherapy may be expanded (to include larger T stage and higher N stage) based on results of ongoing trials, such as RTOG 1333 (NRG-HN002) which compares radiotherapy alone versus concurrent chemoradiotherapy (with reduced dose cisplatin, 40 mg/m^2^) in p16 positive locally advanced OPSCCA patients with minor/no smoking history (10 or less pack years).

Chemotherapy {#Sec4}
------------

Much of the data utilized in clinical decision making for HPV-associated OPSCCA is extrapolated from advanced HNC trials not specifically focused on HPV status. High-dose cisplatin is considered the standard agent for concurrent therapy in HNSCCA. The Intergroup trial of patients with locally advanced HNC noted greatest survival to be in the treatment group of those who received concurrent radiation and cisplatin \[[@CR30]\]. However, robust prospective comparative studies with alternative agents have not been completed. Cetuximab, a monoclonal antibody which targets epidermal growth factor inhibitor, is an agent of interest used quite widely in HNC. Bonner et al. demonstrated a 10 % survival benefit at three years in advanced stage HNC when cetuximab was administered concurrently with radiation \[[@CR31]\]. Side effect profile is comparatively favorable, with the exception of acneiform rash, cetuximab does not have an association with increased grade 3/grade 4 toxicities. Unfortunately, to date no clinical trial data is available directly comparing cetuximab vs cisplatin for HPV-associated oropharynx cancer, but RTOG 1016 which has completed primary accrual should provide evidence to address this question.

Regarding advanced non-HPV-related HNC, the addition of cytotoxic chemotherapy is noted to improve survival over radiation alone, by enhancing locoregional control \[[@CR32], [@CR33]\]. When utilized as initial definitive treatment in the context of advanced OPSCCA, concurrent chemoradiation was noted to be superior to induction chemotherapy followed by radiation \[[@CR32]\].

Chemotherapy also is utilized alongside radiation in the setting of high risk/adverse features (extracapsular extension, positive/close margin) with improved disease free survival and locoregional control noted in combined treatment arm of European Organization for Research and Treatment of Cancer (EORTC) 22931 and RTOG 9501 \[[@CR34], [@CR35]\]. An improvement in locoregional control and survival of adjuvant chemoradiation has not been observed for patients with HPV-associated OPSCCA and extracapsular extension of metastatic cervical lymphadenopathy \[[@CR36]\]. A review by Lewis et al described the lack of impact of extracapsular spread on survival as well as a lack of association between size of nodal metastasis and extracapsular spread \[[@CR37]\]. Sinha et al. assessed outcomes in HPV-associated SCCA with nodal extracapsular spread and no survival advantage was noted with the addition of chemotherapy to radiotherapy \[[@CR38]\]. However, the sample size required to detect a survival difference is very large given the paucity of events, and the favorable survival of patients with HPV-related OPSCCA. It is likely that prior studies were underpowered to detect an effect of chemotherapy on survival. Currently, the postoperative adjuvant therapy de-intensification trial for HPV-related OPSCCA (ADEPT trial, phase III randomized) aims to definitively answer the question of the utility of chemotherapy for these patients (assessing two year locoregional control and disease free survival), though the estimated primary completion date is October 2018.

The use of concurrent chemoradiation for locoregionally advanced HNC carries with it increased acute and late toxicities, over radiation alone or surgery. While the GORTEC trial noted concurrent chemoradiation to provide superior overall survival and locoregional control compared to radiation alone, it resulted in increased late complications, increased need for gastrostomy tube, and mucositis \[[@CR39]\]. Randomized clinical trials report chemoradiation to have a treatment-related mortality rate of approximately 3--4 % \[[@CR40]\].

There is opportunity to further define the role of chemotherapy in HPV-associated OPSCCA, as this group of patients generally has a favorable prognosis and the question remains if the treatment related toxicities of concurrent chemoradiation provide meaningful benefit in terms of disease control and survival.

Surgical approaches {#Sec5}
-------------------

Historically, adequate access for many oropharyngeal tumors required a transcervical approach +/-mandibulotomy. With improvements in both imaging and instrumentation, transoral surgery has become much more widespread. When referring to NCCN guidelines, it is offered as an equivalent option (to open surgery) in all treatment algorithms. However, the safety, efficacy and tolerability of modern, minimally invasive transoral approaches suggest that transoral procedures should be considered over traditional transcervical approaches for properly selected patients.. We will limit discussion mainly to transoral approaches, which include transoral robotic surgery (TORS) and transoral laser microsurgery (TLM) which represent two different minimally invasive techniques. To date, no formal trial has tested TORS vs TLM in a head to head fashion. Clinical trials that include minimally invasive transoral surgery (such as ECOG 3311) leave the decision to use TORS or TLM at the discretion of the surgeon, and neither specify criteria for patient selection. Both TLM and TORS are well-established techniques with proven oncologic outcomes \[[@CR41]--[@CR43]\]. Both require specialized equipment and associated expense, training/credentialing, and are associated with a learning curve. A significant advantage of TORS over TLM includes the use of angled telescopes and rotating robotic surgical arms which obviate some limitations of surgery dependent on the line of sight.

Compared to traditional approaches, both TORS and TLM are less disruptive of normal and uninvolved anatomic structures, and consequently, the use of these approaches has been associated, with a shorter hospital stay, faster recovery, less pain, less need for gastrostomy/tracheostomy tube, and has less cost. \[[@CR44]\] The immediate postoperative morbidity can be substantial, and varies with the extent of the resection. Yet, minimally invasive surgical treatment yields far less long-term sequelae than classic transcervical surgery; in the absence of postoperative radiation, or chemoradiation, minimally invasive transoral surgery yields minimal late sequelae \[[@CR45]\].

Oncologic outcomes following minimally invasive surgery have similarly been favorable. In 2012, a review of TORS outcomes noted a two year overall survival of 80--90 % for a cohort consisting of 36 T1/2, 11 T3/4 with neck disease ranging from N0-N2c \[[@CR46]\]. TLM results have noted five year overall survival of 78 %, with local control rates of 85--97 % \[[@CR47], [@CR48]\]. TORS/TLM is not only limited to early stage cancers, as several series with advanced stage OPSCCA have noted up to 90 % local control and disease specific survival \[[@CR41], [@CR48]\]. Interestingly in these series, between 38 and 84 % of patients avoided chemotherapy. In a series by Haughey et al., postoperative swallowing results were excellent in 87 % of patients; long-term dysphagia was associated with T4 tumors though, particularly those which involved the tongue base \[[@CR48]\]. As one may expect, postoperative functional outcomes were noted to further worsen with the addition of each adjuvant modality.

Lacking high-level data to support oncologic superiority of surgery over non-surgical approaches, the decision to employ a surgical approach is driven primarily by the need for adequate surgical exposure as well as functional and quality of life considerations. Patient selection is extremely important as transoral surgery should be utilized for OPSCCA which is adequately visualized and anatomically favorable for complete resection, thus enabling the patient to avoid potentially unnecessary adjuvant therapy. Non-surgical treatment with radiation or chemoradiation remains a mainstay of treatment, if surgical intervention is not favorable. Tumor characteristics which will commonly dissuade from primary surgical intervention include: tongue base invasion which will require greater than 50 % resection, pterygoid muscle involvement, extension into the parapharyngeal fat abutting the carotid, mandible/maxilla extension or invasion, and prevertebral space involvement.

The adequacy of the surgical extirpation has a great impact on the delivery of postoperative radiation. With a positive margin, most radiation oncologists will deliver a full dose of radiation to the primary site, with concurrent chemotherapy. A negative margin warrants a lower radiation dose, and possibly a reduction in the target volume. Given the bulk of some tumors within the oropharynx, uninvolved pharyngeal structures immediately adjacent to the mass may have a higher radiation exposure. The ability to perform radiation planning in the absence of that tumor bulk may allow the radiation oncologist to tailor the treatment volume to the area of interest potentially yielding improved swallowing outcomes \[[@CR49]\].

Surgical management of the neck varies by location of the primary and the presenting N stage. Neck dissection may be performed at the time of primary tumor resection, or may be staged. There may be for various reasons for staging of the neck dissection, such as a concern for communication between the oropharynx and the neck, or for reasons of equipment logistics (time constraints of the "robot" room for example). For tonsil/lateral pharyngeal wall-based primaries, dissection of the N0 neck will typically involve levels 2--4 ipsilaterally. For N+ necks, nodal dissection will be adjusted based on positive node location and size. In the context of tongue base primaries which approach/cross the midline, bilateral neck dissection is indicated, particularly when considering using surgery as a single curative modality.

An additional benefit of primary surgical treatment for OPSCCA is the ability to have definitive pathology (such as margin status and presence/degree of extranodal extension) from both tumor and cervical nodes for staging and subsequent decision-making purposes regarding adjuvant therapy. This may be of benefit over clinical/radiographic staging given the potential for over/under-staging. In a study by Walvekar et al. involving nearly 50 patients with OPSCCA who underwent primary surgical resection, 40 % of patients had their preoperative staging changed, 24 % of which were down-staged \[[@CR50]\]. The ability to accurately stage and offer subsequent therapeutic de-intensification is of great importance in terms of clinical trials for OPSCCA and for future tailored therapy.

Clinical decision-making {#Sec6}
========================

Ideally optimal treatment will provide maximum survival opportunity while minimizing locoregional recurrence and distant failure \[[@CR51]\]. In HPV-associated OPSCCA, single modality therapy should be utilized when appropriate; the avoidance of triple modality therapy is recommended to minimize toxicity. The clinical expertise/experience of the treatment team cannot be underestimated with regards to maximizing disease control and minimizing morbidity \[[@CR52]\]. Once the patient has been staged appropriately, how does one decide between surgical vs non-surgical management?

Survival and disease control {#Sec7}
----------------------------

One of the first considerations for both clinician and patient will be regarding survival and disease control. When comparing transoral resection followed by adjuvant treatment (as dictated by NCCN guidelines) to nonsurgical management, the results of local control, regional control, and survival are comparable \[[@CR53], [@CR54]\]. As a result, attention to treatment-related morbidity, functional outcome, and quality of life is of great importance, and commonly the main driver behind treatment approach.

Patient factors {#Sec8}
---------------

Multi-disciplinary evaluation is the foundation of comprehensive care of the cancer patient. Pretreatment assessment of baseline functionality is critically important. An evaluation of anesthesia risk, oral/oropharyngeal function, swallowing and airway protection, along with potential for rehabilitation is essential. After appropriate pre-treatment counseling, patient preference in terms of surgical vs non-surgical management must also be considered.

The patient smoking history is also taken into consideration, as we know this to be an independent prognosticator when greater than 10 pack/years \[[@CR3], [@CR55]\]. Interestingly, epidemiologic data describes smoking as an independent risk factor for the development of OPSCCA in general, but not specifically the development of HPV-associated OPSCCA \[[@CR56]\]. Ang et al note though that the biologic behavior of HPV-associated OPSCCA is likely altered by tobacco use, with decreased responsiveness to therapy \[[@CR3]\]. As a result, smoking serves as an independent risk factor for overall survival and progression free survival in HPV associated OPSCCA in multivariable analysis. The negative effect on survival increases as pack-years of smoking increases \[[@CR55]\]. Ang et al. utilized a 10 pack-year cut off to designate a low risk group, as it was noted to be the best survival predictor in recursive partitioning analysis. The pack-year cutoff was also elected over a continuum for ease of future trial design, acknowledging the need for further validation.

Current de-escalation protocols consider patients to be in the lowest risk smoking category when at 10 or less pack-years. Specific situations may exist though which still consider a patient to be low-risk despite a greater than 10 pack-year history, such as in ECOG 3311, with a patient possessing a T1-2, N0-1 tumor with negative margins and no extracapsular extension. RTOG 1333 (NRG-HN002) uses a cut-off of 10 pack years as well. Of interest, the low-risk group in the investigation by Ang et al. also contained patients with greater than 10 pack-year, though limited to N0-N2a; so it remains to be seen whether the de-escalation envelope will be pushed in the future for those with higher than 10 pack-year smoking history if they possess limited neck disease. See Table [1](#Tab1){ref-type="table"} for additional trials related to HPV-associated OPSCCA.Table 1De-escalation trials in HPV-associated OPSCCATrialPhasePopulationInterventionPrimary outcomeSurgical trials NCT01898494 ECOG 3311IIStage III-Iva (no T1-2, N1)Transoral surgery followed by risk stratification\
-*Low*: no adjuvant\
-*Intermediate*: 50 vs 60 Gy IMRT randomization\
-*High*: 66 Gy IMRT with weekly cisplatin (40 mg/m2)2 year DFS NCT01932697II\<10 pack year smoker, must have one: T3/T4a, N2a-N3, ECE/PNI/LVITransoral surgery with negative margin followed by hyperfractionated IMRT + docetaxel2 year LRC/DFS NCT01687413, ADEPTIIIT1-4a with negative margins and cervical metastasis with ECETransoral surgery followed by IMRT: randomized into 60 Gy alone vs with concurrent cisplatin (40 mg/m2)2 year DFS/LRC NCT02215265, PATHOSII/IIIT1-3, N0-2b, \<10 pack year smokerTransoral surgery followed by risk stratification\
-*Low*: no adjuvant\
-Intermediate: 50 vs 60 Gy IMRT randomization\
*-High*: chemoradiation vs IMRT (60 Gy) randomization2 year PFS NCT01590355, ORATORIIT1-2, N0-1 or N2b (up to 2 nodes); stratify groups by HPV statusTransoral surgery plus neck dissection vs IMRT +/- chemotherapy1 year QOL EORTC 1420-HNCG-ROGIIIStage I/II, HPV positive and negativeTransoral surgery plus neck dissection randomized vs IMRT1 year QOL NCT02072148, SIRSIIT1N0-2b, T2N0-2b; \<20 pack year smoker (or \>10 year smoke free)Transoral surgery followed by risk stratification\
-*Low*: no adjuvant\
-Intermediate: 50 Gy IMRT\
*-High*: IMRT (56 Gy) + cisplatin (40 mg/m2)3 & 5 year DFS/LRCNon-surgical trials NCT01084083, ECOG 1308IIStage III/IVa-bLow dose IMRT (50 Gy) + cetuximab vs standard dose (60 Gy)2 year OS NCT02254278, NRG HN002IIStage III/IV (T1-2, N1-2b, or T3, N0-2b); \<10 pack year smokerIMRT (60 Gy) +/- cisplatin2 year PFS NCT01302834, RTOG 1016IIIStage III/IVIMRT (60 Gy) with high dose cisplatin vs IMRT with cetuximab5 year OS NCT01874171, De-ESCALATEIIIT3N0-T4N0 and T1N1-T4N3), \<10 pack year smokerStandard dose IMRT (70 Gy) with cisplatin (100 mg/m2) vs IMRT + cetuximabSevere toxicity NCT01855451, TROG 12.01IIIStage III (except T1-2 N1), stage IVa (except T4), \<10 pack year smoker (if \>10 pack year, must be N0-N2a)Standard dose radiation (70 Gy) with cisplatin (40 mg/m2) vs cetuximabSymptom severity NCT01663259, University of MichiganIIStage III/IV (no T4,N3), \<10 pack year smokerStandard dose radiation (70 Gy) + cetuximabRecurrence rate NCT01530997, Lineberger Comprehensive Cancer CenterIIT1-3, N0-2c; \<10 pack year smoker (or \> 5 years smoke free)IMRT (54-60 Gy) with cisplatin (30 mg/m2)Complete pathologic response NCT01088802, Kimmel Comprehensive Cancer CenterIIT1-3, any N (resectable)IMRT, dose de-escalation from 70 Gy to 63 Gy, and from 58.1 Gy to 50.75 Gy, while receiving cisplatinSevere toxicity, QOLAbbreviations: *ECOG* Eastern cooperative oncology group, *ADEPT* adjuvant de-escalation, extracapsular spread, p16-positive, transoral, *ECE* extracapsular extension, *DFS* disease-free survival, *LRC* loco-regional control, *HPV* human papilloma virus, *OPSCCA* oropharyngeal squamous cell carcinoma, *PATHOS* postoperative adjuvant treatment for HPV-positive tumors, *PFS* progression free survival, *IMRT* intensity modulated radiation therapy, *ORATOR* oropharynx:radiotherapy vs transoral robotic surgery, *QOL* quality of life, *EORTC* European organization for research and treatment of cancer, *HNCG-ROG* head and neck cancer group- radiation oncology group, *ECE* extracapsular extension, *PNI* perineural invasion, *LVI* lymphovascular invasion, *OS* overall survival, *RTOG* radiation therapy oncology group, *SIRS* Sinai robotic surgery trial, *TROG* trans-tasman radiation oncology group

Treatment-related morbidity considerations {#Sec9}
------------------------------------------

When no single modality emerges as notably superior in terms of survival/control outcomes, comparable treatment morbidity is scrutinized. There are some unique treatment-related morbidities to consider with regards to surgery such as bleeding. Bleeding is commonly reported as less than 5 %, though even in experienced hands, bleeding may occur in over 10 % of cases \[[@CR57]--[@CR60]\]. In a survey of over 2000 TORS procedures performed by 45 surgeons, there were 6 deaths (0.3 %) reported secondary to postoperative hemorrhage \[[@CR60]\].

Regarding dysphagia in transoral surgery, most patients resume diet on the first postoperative day and long term feeding tube use is typically less than 10 % \[[@CR48], [@CR59], [@CR60]\]. The need for long term feeding tube placement is associated with increase in T stage, location (tongue base vs tonsil), and extent of postoperative adjuvant therapy \[[@CR61], [@CR62]\]. Functional outcomes and quality of life are thought to be quite similar when comparing surgical resection with postoperative radiation and chemoradiation \[[@CR63], [@CR64]\].

Anatomic considerations {#Sec10}
-----------------------

While technical innovation in minimally invasive surgery has allowed transoral resection of a wide variety of tumors in many different locations, the occasional patient's anatomy may preclude adequate exposure. In these scenarios transoral options may be ill advised, and consequently non-surgical management may be a preferable treatment approach. Rich et al. noted several relative (patient-related) contraindications: trismus, tongue bulk, limited neck extension, prominent teeth, mandibular tori, and limited transverse mandible dimension \[[@CR6]\]. Retropharyngeal (or aberrant) internal carotid artery also poses a relative surgical contraindication. Moore et al. noted several relative (tumor-related) contraindications: deep extrinsic tongue muscle, mandible/skull base invasion, lateral neck, extensive laryngeal invasion, invasion of more than half base of tongue \[[@CR53]\].

Given the anatomic restraints of the oropharynx, anticipation of adequate margin and subsequent defect is crucial. The surgeon needs to critically analyze the tumor as it relates to the surrounding anatomy and the likelihood of obtaining a negative margin, as close or positive margins may prompt additional therapeutic modalities in order to obtain adequate disease control, and along with this will come additional treatment related side effects/morbidity.

Cost considerations {#Sec11}
-------------------

Fundamental difficulties exist when attempting to review previous literature regarding comparative cost of treatment modality. For example, variability exists in what may be considered associated with the actual cost of care and reimbursement schedules vary widely. In addition, fixed equipment costs and secondary downstream costs such as lost wages may also be taken into consideration further complicating comparative analysis.

Moore et al., note that 25 % of all OPSCCA patients may be treated with surgery alone, while 75 % will require adjuvant therapy when applying NCCN criteria \[[@CR65], [@CR66]\]. Up-front surgical resection of OPSCCA followed by pathology-dictated post-operative adjuvant therapy according to NCCN guidelines was noted to be 5.29×'s (non-government) and 3.66×'s (government) less expensive than chemoradiation \[[@CR67]\]. Interestingly, when comparing surgery vs non-surgical modalities for HPV-associated OPSCCA with N2 neck disease, in nearly all assumptions chemoradiation was considered the cost-effective therapy based on quality of life adjusted years divided by total costs; though if the loco-regional recurrence of TORS was able to be hypothetically reduced by 30--50 %, surgery would become the higher value treatment \[[@CR68]\]. These findings further support additional prospective comparative analysis.

Clinical considerations for the patient with early stage disease {#Sec12}
================================================================

Excellent prognosis typically accompanies early stage low tumor burden HPV-associated OPSCCA (T1-2 N0-1 M0), and optimal therapy is single modality, commonly with surgery or radiotherapy. Decision for the surgical option over radiation in this scenario largely depends on location and surgical accessibility of the primary. Lateralized tonsil and tongue base will largely do very well functionally with transoral surgery and ipsilateral selective neck dissection. In the context of a large T2 endophytic primary in the midline of the tongue base that will also require bilateral neck dissection, the decision of surgery vs radiotherapy may be somewhat more difficult given the greater associated surgical morbidity and long-term functional consequences. Nevertheless, in the absence of adverse pathologic features (positive margins, extracapsular spread), the patient will be able to avoid adjuvant radiation. Alternatively, radiation monotherapy to primary and ipsilateral/bilateral necks (based on primary location) may be used, reserving systemic therapy only for T2N1 (as a category 2B recommendation), or in the context of adverse features or positive margin (category 1 recommendation). Given the high rates of disease control for early stage disease, surgery should be recommended only if the odds of requiring adjuvant radiation are anticipated to be low.

Clinical considerations for the patient with locally advanced resectable disease {#Sec13}
================================================================================

Many of HPV-associated OPSCCA are noted to possess cervical metastasis on initial presentation, and consequently staged as III or IV. This group will require multimodality therapy, with the exception of favorable T1-2 N1 (as noted above). Outside the context of clinical trial, there are three main treatment options (1 surgical, 2 non-surgical): (1) surgical resection of the primary with ipsilateral/bilateral neck dissection with appropriate adjuvant therapy (radiation, chemoradiation) based on pathologic/nodal features; (2) concurrent chemoradiotherapy, saving surgery for salvage; and (3) induction chemotherapy followed by radiation vs chemoradiation. The use of induction chemotherapy is controversial (category 3 recommendation) and both PARADIGM and DeCIDE trials have failed to demonstrate a survival advantage \[[@CR69], [@CR70]\]. As a result, we will not expand on this potential option further in this setting.

One of the first considerations with surgery in locally advanced resectable disease is the ability to obtain adequate and negative margins, as failure to do so will ultimately likely require postoperative chemoradiation. But the ability to clear mucosal margins must be balanced with morbidity and functional consequence of resection. Higher T stage tumors have higher postoperative functional morbidity, particularly those involving the tongue base. When a sound oncologic resection will have significant morbidity, it is appropriate to consider chemoradiation the preferred alterative.

Regarding management of advanced neck disease, the possibility of extracapsular extension must be considered as based on current guidelines the patient will likely warrant chemotherapy in addition to postoperative radiation if extracapsular extension is found on pathologic review of the neck dissection specimen. A patient with negative margins on the primary with extracapsular extension in the neck is a suitable candidate for the ADEPT trial (interventional phase III trial for p16 positive OPSCCA patients treated initially with surgery and have extracapsular spread in the lymph nodes, randomized to receive radiation alone vs radiation plus cisplatin) though if not available, one may argue for concurrent chemoradiation for such a patient over surgery with post-operative chemoradiation. Patients with evidence of gross extracapsular extension of cancer metastases on pretreatment imaging studies should be offered primary chemoradiation.

Clinical considerations for the unknown primary patient {#Sec14}
=======================================================

In the context of unknown primary tumor, several reports have claimed an identification rate of between 75--90 % when removing both palatine and lingual tonsil beds \[[@CR71]--[@CR74]\]. In some situations, excision of the tonsil beds and neck dissection will be curative.

Low recurrence rates generally characterize this population. Consequently, the elective, comprehensive treatment of mucosal sites and contralateral neck may represent over-treatment for some of these patients. Galloway provides an excellent algorithm for decision-making for the unknown primary \[[@CR75]\]. T0N1 treatment should involve single modality therapy, commonly neck dissection. T0N2a management is subdivided by risk profile; with lowest risk (p16+, less than 10 pack year smoker) patients receiving single modality therapy. T0N2a with greater than 10 pack year history will be treated with surgery plus radiation. In the case of T0N2a with radiographic extranodal extension, primary chemoradiation is the recommendation. T0N2b treatment is dictated by institutional philosophy and may be either surgery followed by radiation, vs primary chemoradiation, although surgery may be associated with less long-term toxicity. T0N2c and T0N3 are both recommended to be treated with primary chemoradiation. What constitutes adequate mucosal sampling (unilateral versus bilateral tonsillectomy, base of tongue mucusectomy) remains an area of controversy.

Conclusion {#Sec15}
==========

The management of HPV-associated OPSCCA will continue to evolve and will likely change dramatically in the future, particularly with respect to de-intensification. The role of surgery for HPV-associated OPSCCA will continue to be defined and refined as treatments aim to minimize long-term functional consequences while maintaining disease control. To date, no treatment modality has emerged superior for HPV-associated OPSCCA, so interventions should consider unique characteristics of the tumor presentation in addition to patient preferences in order to optimize outcomes and quality of life given the prolonged survival typically associated with this unique disease. As a result, patient enrollment in clinical trials is of critical importance, as it provides opportunity to expand knowledge base, to find answers to important treatment-related questions, and offer de-intensification options to patients.
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